Literature DB >> 26929782

Overlapping irritable bowel syndrome and inflammatory bowel disease: less to this than meets the eye?

Eamonn M M Quigley1.   

Abstract

Though distinct in terms of pathology, natural history and therapeutic approach, irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD) have some features in common. These include shared symptomatology and largely similar demographics. However, in most instances, clinical presentation, together with laboratory, imaging and endoscopic findings will readily permit the differentiation of active IBD from IBS. More problematic is the situation where a subject with IBD, in apparent remission, continues to complain of symptoms which, in aggregate, satisfy commonly employed criteria for the diagnosis of IBS. Access to methodologies, such the assay for levels of calprotectin in feces, now allows identification of ongoing inflammation in some such individuals and prompts appropriate therapy. More challenging is the IBD patient with persisting symptoms and no detectable evidence of inflammation; is this coincident IBS, IBS triggered by IBD or an even more subtle level of IBD activity unrecognized by available laboratory or imaging methods? Arguments can be advanced for each of these proposals; lacking definitive data, this issue remains unresolved. The occurrence of IBS-type symptoms in the IBD patient, together with some data suggesting a very subtle level of 'inflammation' or 'immune activation' in IBS, raises other questions: is IBS a prodromal form of IBD; and are IBS and IBD part of the spectrum of the same disease? All of the available evidence indicates that the answer to both these questions should be a resounding 'no'. Indeed, the whole issue of overlap between IBS and IBD should be declared moot given their differing pathophysiologies, contrasting natural histories and divergent treatment paths. The limited symptom repertoire of the gastrointestinal tract may well be fundamental to the apparent confusion that has, of late, bedeviled this area.

Entities:  

Keywords:  fecal calprotectin; immune activation; inflammation; inflammatory bowel disease; irritable bowel syndrome; remission

Year:  2016        PMID: 26929782      PMCID: PMC4749858          DOI: 10.1177/1756283X15621230

Source DB:  PubMed          Journal:  Therap Adv Gastroenterol        ISSN: 1756-283X            Impact factor:   4.409


  139 in total

Review 1.  Inflammatory bowel disease and colitis: new concepts from the bench and the clinic.

Authors:  Séverine Vermeire; Gert Van Assche; Paul Rutgeerts
Journal:  Curr Opin Gastroenterol       Date:  2011-01       Impact factor: 3.287

Review 2.  Peripheral mechanisms in irritable bowel syndrome.

Authors:  Michael Camilleri
Journal:  N Engl J Med       Date:  2012-10-25       Impact factor: 91.245

3.  ACP Journal Club. Review: Calprotectin testing differentiates inflammatory bowel disease from the irritable bowel syndrome.

Authors:  Paul Moayyedi
Journal:  Ann Intern Med       Date:  2014-04-15       Impact factor: 25.391

Review 4.  Gut/brain axis and the microbiota.

Authors:  Emeran A Mayer; Kirsten Tillisch; Arpana Gupta
Journal:  J Clin Invest       Date:  2015-02-17       Impact factor: 14.808

5.  Prodromal irritable bowel syndrome may be responsible for delays in diagnosis in patients presenting with unrecognized Crohn's disease and celiac disease, but not ulcerative colitis.

Authors:  S M Barratt; J S Leeds; K Robinson; A J Lobo; M E McAlindon; D S Sanders
Journal:  Dig Dis Sci       Date:  2011-06-22       Impact factor: 3.199

Review 6.  Treatment of IBD: where we are and where we are going.

Authors:  Charles N Bernstein
Journal:  Am J Gastroenterol       Date:  2014-12-09       Impact factor: 10.864

Review 7.  Environmental risk factors for inflammatory bowel diseases: a review.

Authors:  Ashwin N Ananthakrishnan
Journal:  Dig Dis Sci       Date:  2014-09-10       Impact factor: 3.199

8.  Ulcerative colitis and irritable bowel patients exhibit distinct abnormalities of the gut microbiota.

Authors:  Samah O Noor; Karyn Ridgway; Louise Scovell; E Katherine Kemsley; Elizabeth K Lund; Crawford Jamieson; Ian T Johnson; Arjan Narbad
Journal:  BMC Gastroenterol       Date:  2010-11-12       Impact factor: 3.067

9.  Infections Requiring Hospitalization as Predictors of Pediatric-Onset Crohn's Disease and Ulcerative Colitis.

Authors:  Susan Hutfless; Oren Abramson; Melvin B Heyman; Theodore M Bayless; De-Kun Li; Kevin Winthrop; Lisa J Herrinton
Journal:  Gastroenterol Res Pract       Date:  2015-05-14       Impact factor: 2.260

Review 10.  Irritable bowel syndrome, inflammatory bowel disease and the microbiome.

Authors:  Giles Major; Robin Spiller
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2014-02       Impact factor: 3.243

View more
  15 in total

1.  Internalized Stigma in Patients with Eosinophilic Gastrointestinal Disorders.

Authors:  L Guadagnoli; T H Taft
Journal:  J Clin Psychol Med Settings       Date:  2020-03

2.  Irritable Bowel Syndrome.

Authors:  Kristen Ronn Weaver; Gail DʼEramo Melkus; Wendy A Henderson
Journal:  Am J Nurs       Date:  2017-06       Impact factor: 2.220

3.  The Prevalence, Comorbidity, Management and Costs of Irritable Bowel Syndrome.

Authors:  Winfried Häuser; Ursula Marschall; Peter Layer; Thomas Grobe
Journal:  Dtsch Arztebl Int       Date:  2019-07-08       Impact factor: 5.594

4.  Irritable Bowel Syndrome on Inflammatory Bowel Disease in Deep Remission: No Relation with Remission Deepening and Inflammation.

Authors:  Orhan Sezgin; Burcu Boztepe; Enver Üçbilek; Engin Altintas; Havva Didem Celikcan
Journal:  Turk J Gastroenterol       Date:  2021-10       Impact factor: 1.852

Review 5.  Irritable bowel syndrome and inflammatory bowel disease overlap syndrome: pieces of the puzzle are falling into place.

Authors:  Rafiz Abdul Rani; Raja Affendi Raja Ali; Yeong Yeh Lee
Journal:  Intest Res       Date:  2016-10-17

6.  Irritable Inflammatory Bowel Syndrome as a Distinct Disease Entity.

Authors:  Jung Hwan Oh
Journal:  J Neurogastroenterol Motil       Date:  2016-10-30       Impact factor: 4.924

Review 7.  From bench to bedside: Fecal calprotectin in inflammatory bowel diseases clinical setting.

Authors:  Maria Gloria Mumolo; Lorenzo Bertani; Linda Ceccarelli; Gabriella Laino; Giorgia Di Fluri; Eleonora Albano; Gherardo Tapete; Francesco Costa
Journal:  World J Gastroenterol       Date:  2018-09-07       Impact factor: 5.742

8.  Inflammation in gastrointestinal disorders: prevalent socioeconomic factors.

Authors:  Davide Giuseppe Ribaldone; Rinaldo Pellicano; Giovanni Clemente Actis
Journal:  Clin Exp Gastroenterol       Date:  2019-07-19

9.  The Vampire Study: Significant elevation of faecal calprotectin in healthy volunteers after 300 ml blood ingestion mimicking upper gastrointestinal bleeding.

Authors:  Stephan R Vavricka; Henriette Heinrich; Simon Buetikofer; Flavia Breitenmoser; Emanuel Burri; Xiaoye Schneider-Yin; Jasmin Barman-Aksoezen; Luc Biedermann; Michael Scharl; Jonas Zeitz; Gerhard Rogler; Benjamin Misselwitz; Matthias Sauter
Journal:  United European Gastroenterol J       Date:  2018-05-28       Impact factor: 4.623

10.  Mucosa repair mechanisms of Tong-Xie-Yao-Fang mediated by CRH-R2 in murine, dextran sulfate sodium-induced colitis.

Authors:  Shan-Shan Gong; Yi-Hong Fan; Shi-Yi Wang; Qing-Qing Han; Bin Lv; Yi Xu; Xi Chen; Yao-Er He
Journal:  World J Gastroenterol       Date:  2018-04-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.